Abstract：
Aim: There is little consensus on salvage management of glioblastoma after recurrence, for lack of evidence. Materials & methods: A retrospective study of treatments in patients with recurrent glioblastoma. Results: Surgery at recurrence was related to better overall survival (OS) and progression-free survival (PFS). Surgery at recurrence, Karnofsky index, MGMT methylation status, younger age at diagnosis and number of chemotherapy cycles were positive factors for OS and PFS. The benefit of OS was relevant for a second surgery performed at least 9 months after the first one. Systemic treatments after the second surgery were linked to an improved PFS. Conclusion: Younger age, Karnofsky index, MGMT methylation status and a median time between surgeries ≥9 months may be criteria for eligibility for surgery at recurrence.
[Box: see text].
[Box: see text].
摘要：
目的：对胶质母细胞瘤复发后的抢救治疗几乎没有共识，因为缺乏证据。材料与方法：复发性胶质母细胞瘤患者治疗的回顾性研究。结果：复发时手术与更好的总生存期（OS）和无进展生存期（PFS）相关。复发时的手术，Karnofsky指数,MGMT甲基化状态，诊断年龄和化疗周期数是OS和PFS的积极因素.OS的益处与第一次手术后至少9个月进行的第二次手术有关。第二次手术后的全身治疗与改善的PFS有关。结论：年龄较小，Karnofsky指数,MGMT甲基化状态和手术之间的中位时间≥9个月可能是复发时手术资格的标准。
[方框：见正文]。
[方框：见正文]。
